HELP PEOPLE WITH CANCER
LIVE LONGER AND BETTER
3D Medicines Inc. is a commercialization stage bio-pharmaceutical company, focused on the field of cancer treatment. With a mission to help people with cancer live longer and better, we commit to developing a new generation of therapies for cancer patients around the world, following a future when cancer is managed as a chronic disease. Our differentiated or world-leading portfolio of 12 drug candidates with clinical benefit includes eight in clinical or commercialization stage. Our global first subcutaneously-injectable PD-L1 antibody Envafolimab co-developed by partner has submitted BLA in China. The global first-in-class peptide cancer vaccine 3D189 and GAS6 decoy protein 3D229 are in an ongoing global Phase III trial. Our in-house developed multi-target kinase inhibitor 3D011 has also entered clinical development. We currently have a strong international team of R&D, manufacture and commercialization members.
BTC，combo with chemo vs. chemo, randomized，OS，1L
UC，mono vs. BSC, 1L maintenance
TMB-H,single arm,mono， 2L+
endometrial cancer, single arm, combo with lenvatinib, 2L+
HCC，combo with VEGF inhibitor，2L+
RCC，combo with VEGF inhibitor，1L/2L+
post-surgical dental pain、cancer pain
"With the increasing incidence of cancer, cancer has become one of the major public health problems facing mankind; it not only poses a major threat to human health, but also causes a serious burden to economic and social development.
With commitment to the R&D and commercialization of a next-generation of innovative immuno-oncology drugs, 3D Medicines hopes to provide cancer patients across the globe with more effective, more accessible, and more convenient options of next-generation immuno-oncology drugs, thus helping them to live longer and better."
-- John Gong, M.D., Ph.D., Chairman and CEO of 3D Medicines Inc.
Shanghai, China July 14, 2021- 3D Medicines Inc., a China-based late clinical stage biopharmaceutical company, announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application submitted by 3D Medicines to participate in Aravive’s international AVB-500 (3D-229) Phase 3 platinum resistant ovarian cancer (PROC) clinical trial. (ClinicalTrials.gov Identifier: NCT04729608) This is expected to be a registrational Phase III multi-regional clinical trial (MRCT), in China, of AVB-500 (3D-229) IV infusion, a GAS6/AXL inhibitor, in patients with PROC. This is the first international Phase III clinical trial approved for GAS6/AXL inhibitor in China.
Shanghai, March 31, 2021 - 3D Medicines Inc.(3DMed), a biopharmaceutical company focused on treating cancer as a chronic disease, and ImmuneOncia Therapeutics, Inc., a clinical-stage, immuno-oncology company in South Korea, today announced the execution of an exclusive license agreement for the development, manufacture and commercialization of IMC-002, ImmuneOncia’s monoclonal antibody against CD47, for oncology indication in the Territory of Greater China (Mainland China, Hong Kong, Macau, and Taiwan). ImmuneOncia will retain rights to IMC-002 in the rest of the world including the United States, European Union, and Japan.
March 2, 2021 – 3D Medicines Inc. announced the appointment of Shen Xiao, M.D., Ph.D., as Chief Strategy Officer. He would be responsible for tasks including strategic innovation, competitive positioning and business model establishment for the company, he would provide support for the Chief Executive Officer on strategy planning and execution, and be in charge of the Regulatory Affairs Department. Shen Xiao, M.D., Ph.D., would report to John Gong, M.D., Ph.D., Chairman and Chief Executive Officer of 3D Medicines.